- Home
- DOYU vs DSGN Comparison
DOYU vs DSGN Comparison
Compare DOYU & DSGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DOYU
- DSGN
- Stock Information
- Founded
- DOYU 2014
- DSGN 2017
- Country
- DOYU China
- DSGN United States
- Employees
- DOYU N/A
- DSGN N/A
- Industry
- DOYU Computer Software: Programming Data Processing
- DSGN Biotechnology: Pharmaceutical Preparations
- Sector
- DOYU Technology
- DSGN Health Care
- Exchange
- DOYU Nasdaq
- DSGN Nasdaq
- Market Cap
- DOYU 206.3M
- DSGN 224.8M
- IPO Year
- DOYU 2019
- DSGN 2021
- Fundamental
- Price
- DOYU $7.29
- DSGN $3.52
- Analyst Decision
- DOYU Sell
- DSGN Hold
- Analyst Count
- DOYU 3
- DSGN 1
- Target Price
- DOYU $10.33
- DSGN $4.00
- AVG Volume (30 Days)
- DOYU 64.1K
- DSGN 138.7K
- Earning Date
- DOYU 06-04-2025
- DSGN 05-07-2025
- Dividend Yield
- DOYU 268.86%
- DSGN N/A
- EPS Growth
- DOYU N/A
- DSGN N/A
- EPS
- DOYU N/A
- DSGN N/A
- Revenue
- DOYU $585,116,720.00
- DSGN N/A
- Revenue This Year
- DOYU N/A
- DSGN N/A
- Revenue Next Year
- DOYU N/A
- DSGN N/A
- P/E Ratio
- DOYU N/A
- DSGN N/A
- Revenue Growth
- DOYU N/A
- DSGN N/A
- 52 Week Low
- DOYU $5.68
- DSGN $2.60
- 52 Week High
- DOYU $20.17
- DSGN $7.77
- Technical
- Relative Strength Index (RSI)
- DOYU 49.78
- DSGN 43.12
- Support Level
- DOYU $7.52
- DSGN $4.27
- Resistance Level
- DOYU $7.97
- DSGN $5.04
- Average True Range (ATR)
- DOYU 0.37
- DSGN 0.48
- MACD
- DOYU 0.13
- DSGN -0.03
- Stochastic Oscillator
- DOYU 64.14
- DSGN 16.16
About DOYU DouYu International Holdings Limited ADS
DouYu International Holdings Ltd is a game-centric live streaming platform in China and a pioneer in the eSports value chain. The company operates its platform on both PC and mobile apps, through which users can enjoy immersive and interactive games and entertainment live streaming. It generates revenues through live streaming and advertisement.
About DSGN Design Therapeutics Inc.
Design Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the research and development of GeneTACTM molecules, which are a novel class of small-molecule gene-targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. The Company's product candidate is in Friedreich ataxia (FA), its second product candidate is in Fuchs endothelial corneal dystrophy (FECD), and it is also advancing its GeneTACTM program to address other serious nucleotide repeat-driven monogenic diseases.